Moleculin Biotech News, Moleculin Biotech Quote, MBRX Quote

Moleculin Biotech (NQ:MBRX) Delayed: 2.62 -0.08 (2.96%)

Prev. Close

$2.70

Today 6M 1Y 5Y

Open

$2.69

52 Wk High

$9.58

52 Wk Low

$2.34

Day High

$2.79

Day Low

$2.60

P/E

N/A

EPS

$-0.34

Volume

145,556

Friends, Peers and Foes (?): AKTX, AMIX, CNSP, GRI, NUWE (more...)

ALERTS | RSS

Jun 5, 2026 08:30 AM Form 8-K Moleculin Biotech, Inc. For: Jun 05
Jun 5, 2026 08:29 AM Independent Market Research Finds Strong Physician Intent to Prescribe Moleculin's Annamycin in Relapsed/Refractory AML
Jun 5, 2026 08:29 AM Independent Market Research Finds Strong Physician Intent to Prescribe Moleculin's Annamycin in Relapsed/Refractory AML
Jun 4, 2026 08:31 AM Moleculin CEO, Walter Klemp, Highlights 45 Subject Enrollment Milestone in Recent Virtual Investor “What This Means” Segment
May 29, 2026 09:26 AM Form 8-K Moleculin Biotech, Inc. For: May 29
May 29, 2026 08:21 AM Moleculin Presents ASCO 2026 Data Demonstrating No Detectable Cardiotoxicity with Annamycin Despite Exposure Levels Far Exceeding Conventional Anthracycline Limits
May 26, 2026 08:01 AM Form 8-K Moleculin Biotech, Inc. For: May 26
May 22, 2026 04:01 PM Form 8-K Moleculin Biotech, Inc. For: May 22
May 21, 2026 05:02 PM Moleculin presents cardiac safety data for Annamycin at 2026 ASCO meeting
May 21, 2026 05:02 PM Moleculin Highlights Abstract Accepted for Poster Presentation at the 2026 ASCO Annual Meeting Highlighting Cardiac Safety Data for Annamycin

Entities mentioned with MBRX

View All Entities